| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 毛蕊花糖苷生物合成途径及其合成酶相关基因 | CN201610849755.8 | 2016-09-26 | CN106498009A | 2017-03-15 | 周延清; 王向楠; 段红英; 张亮; 张丹丹; 杨柯 |
| 本发明公开了毛蕊花糖苷生物合成途径及其合成酶相关基因，以地黄6个不同发育阶段的块根为材料，提取和检测其总RNA，用Illumina HiSeq2500平台对其组合转录组测序，获得149.8百万reads，从头组装获得96961个Unigenes序列；将Unigenes序列与KEGG数据库比对进行代谢通路分析，获得280个KEGG途径，将代谢通路与推测的毛蕊花糖苷合成途径比对，筛选出5个候选KEGG途径；比较推测的毛蕊花糖苷合成途径和筛选出5个候选KEGG途径，建立有19个基因编码酶催化的毛蕊花糖苷生物合成途径，将Unigenes序列与数据库进行BlastX比对，再附加ESTscan软件功能，得到13个候选的毛蕊花糖苷生物合成酶相关基因。本发明为阐明地黄完整的毛蕊花糖苷生物合成途径和利用次生代谢工程或者合成生物学生产毛蕊花糖苷奠定基础。 | ||||||
| 2 | 抗血管生成分子组及其应用 | CN200980116536.7 | 2009-05-05 | CN102036682A | 2011-04-27 | 大卫·贝尼特·费里斯; 弗朗西斯科·德·博尔哈·科科斯特吉·古拉亚; 赫尔海·阿尔贝托·普列托·加西亚 |
| 本发明涉及抗血管生成分子组及其应用。根据本发明的一种抗血管生成的药物组合物，所述药物组合物包含选自由VEGF 165的反义核酸分子、形成整联蛋白alpha-9/beta-1的alpha-9域的反义核酸分子和VAP-1的反义核酸分子、VEGF 165特异性抗体的分子、对形成整联蛋白alpha-9/beta-1的alpha-9域具有特异性的抗体的分子和VAP-1特异性抗体的分子和/或它们的组合组成的组中的至少一种分子和药用可接受的载体。本发明还保护所述分子在药物制造中的应用。 | ||||||
| 3 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | US14740933 | 2015-06-16 | US20150361464A1 | 2015-12-17 | Adriana Leonora Botes; Alex Van Eck Conradie |
| This document describes biochemical pathways for producing glutaric acid, 5-aminopentanoic acid, 5-hydroxypentanoic acid or 1,5-pentanediol by forming one or two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C5 backbone substrate such as cadaverine or 5-aminopentanamide. | ||||||
| 4 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER | US12740566 | 2008-10-15 | US20100310579A1 | 2010-12-09 | Marko Salmi; Sirpa Jalkanen |
| The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down-regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis. | ||||||
| 5 | Set of Antiangiogenic Molecules and Use Thereof | US12991200 | 2009-05-05 | US20110178158A1 | 2011-07-21 | David Benet Ferrus; Francisco de Borja Corcostegui Guraya; Jorge Alberto Prieto Garcia |
| The present invention relates to an antiangiogenic pharmaceutical composition comprising at least one molecule selected from the group comprising an antisense nucleic acid molecule of VEGF 165, an antisense nucleic acid molecule of alpha-9 domain that forms integrin alpha-9/beta-1 and an antisense nucleic acid molecule of VAP-1, a molecule of VEGF 165-specific antibody, a molecule of antibody specific for the alpha-9 domain that forms integrin alpha-9/beta-1 and a molecule of VAP-1-specific antibody and/or combinations thereof and a pharmaceutically acceptable vehicle. The present invention also protects the use of said molecules for the production of a medicament. | ||||||
| 6 | COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS | US11917638 | 2006-06-12 | US20110038922A1 | 2011-02-17 | Sirpa Jalkanen; Markku Jalkanen; Marko Salmi |
| This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included. | ||||||
| 7 | Anti-angiogenic family of molecules and their use | JP2011507947 | 2009-05-05 | JP2011519902A | 2011-07-14 | ダビド、ベネト、フェルス; フランシスコ、デ、ボルハ、コルコステギ、グラヤ; ホルヘ、アルベルト、プリエト、ガルシア |
| The present invention relates to an antiangiogenic pharmaceutical composition comprising at least one molecule selected from the group consisting of an antisense nucleic acid molecule of VEGF 165, an antisense nucleic acid molecule of alpha-9 domain that forms integrin alpha-9/beta-1 and an antisense nucleic acid molecule of VAP-1, a molecule of VEGF 165-specific antibody, a molecule of antibody specific for the alpha-9 domain that forms integrin alpha-9/beta-1 and a molecule of VAP-1-specific antibody and/or combinations thereof and a pharmaceutically acceptable vehicle. The present invention also protects the use of said molecules for the production of a medicament. | ||||||
| 8 | Method for treating inhibiting angiogenesis, or cancer | JP2010531552 | 2008-10-15 | JP2011500867A | 2011-01-06 | サルミ、マルコ; ヤルカネン、シルパ |
| 本発明は、血管形成を阻害する方法または個体における癌または癌の転移を治療または予防する方法に関する。 この方法は血管接着タンパク質１（ＶＡＰ−１）の影響を中和できる、またはその発現をダウンレギュレートできる薬剤の投与に基づく。 ＶＡＰ−１の触媒活性を阻害することが、血管形成の阻害および癌または癌転移の治療または予防のために特に望ましい。 | ||||||
| 9 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER | EP08843507 | 2008-10-15 | EP2211871A4 | 2011-11-16 | SALMI MARKO; JALKANEN SIRPA |
| 10 | METHODS, REAGENTS AND CELLS FOR BIOSYNTHESIZING COMPOUNDS | EP15741382.4 | 2015-06-16 | EP3155090A1 | 2017-04-19 | BOTES, Adriana Leonora; CONRADIE, Alex Van Eck |
| This document describes biochemical pathways for producing glutaric acid, 5 aminopentanoic acid, 5-hydroxypentanoic acid or 1,5-pentanediol by forming one or two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C5 backbone substrate such as cadaverine or 5-aminopentanamide. | ||||||
| 11 | SET OF ANTIANGIOGENIC MOLECULES AND USE THEREOF | EP09745859.0 | 2009-05-05 | EP2292265A1 | 2011-03-09 | Benet Ferrus, David; De Borja Corcostegui, Francisco; Prieto García, José Alberto |
The present invention relates to an antiangiogenic pharmaceutical composition comprising at least one molecule selected from the group consisting of an antisense nucleic acid molecule of VEGF 165, an antisense nucleic acid molecule of alpha-9 domain that forms integrin alpha-9/beta-1 and an antisense nucleic acid molecule of VAP-1, a molecule of VEGF 165-specific antibody, a molecule of antibody specific for the alpha-9 domain that forms integrin alpha-9/beta-1 and a molecule of VAP-1-specific antibody and/or combinations thereof and a pharmaceutically acceptable vehicle. The present invention also protects the use of said molecules for the production of a medicament. |
||||||
| 12 | COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS | EP06764414 | 2006-06-12 | EP1890711A4 | 2010-08-18 | JALKANEN SIRPA; JALKANEN MARKKU; SALMI MARKO |
| 13 | SET OF ANTIANGIOGENIC MOLECULES AND USE THEREOF | EP09745859 | 2009-05-05 | EP2292265A4 | 2013-05-29 | BENET FERRUS DAVID; DE BORJA CORCOSTEGUI FRANCISCO; PRIETO GARCIA JOSE ALBERTO |
| 14 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER | EP08843507.8 | 2008-10-15 | EP2211871A1 | 2010-08-04 | SALMI, Marko; JALKANEN, Sirpa |
| The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down- regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis. | ||||||
| 15 | COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS | EP06764414.6 | 2006-06-12 | EP1890711A1 | 2008-02-27 | JALKANEN, Sirpa; JALKANEN, Markku; SALMI, Marko |
| This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included. | ||||||
| 16 | 혈관신생억제 분자의 세트 및 이의 용도 | KR1020107027406 | 2009-05-05 | KR1020110055484A | 2011-05-25 | 베넷페러스,데이비드; 코르코스테규구라야,프란시스코데보르자; 프레토가르시아,호르헤알베르토 |
| 본 발명은 VEGF 165의 안티센스 핵산 분자, 인테그린(integrin) 알파(alpha)-9/베타(beta)-1을 형성하는 알파(alpha)-9 도메인의 안티센스 핵산 분자 및 VAP-1의 안티센스 핵산 분자, VEGF 165의 특이적 항체 분자, 인테그린(integrin) 알파(alpha)-9/베타(beta)-1을 형성하는 알파(alpha)-9 도메인에 특이적인 항체 분자 및 VAP-1의 특이적 항체 분자 및/또는 이의 조합으로 구성된 군으로부터 선택되는 적어도 하나의 분자 및 약학적으로 허용가능한 담체를 포함하는 혈관신생억제 약학적 조성물에 관한 것이다. 또한 본 발명은 약제의 생산을 위한 상기 분자의 용도를 보호한다. | ||||||
| 17 | 혈관신생억제 분자의 세트 및 이의 용도 | KR1020107027406 | 2009-05-05 | KR101279580B1 | 2013-06-27 | 베넷페러스,데이비드; 코르코스테규구라야,프란시스코데보르자; 프레토가르시아,호르헤알베르토 |
| 본 발명은 VEGF 165의 안티센스 핵산 분자, 인테그린(integrin) 알파(alpha)-9/베타(beta)-1을 형성하는 알파(alpha)-9 도메인의 안티센스 핵산 분자 및 VAP-1의 안티센스 핵산 분자, VEGF 165의 특이적 항체 분자, 인테그린(integrin) 알파(alpha)-9/베타(beta)-1을 형성하는 알파(alpha)-9 도메인에 특이적인 항체 분자 및 VAP-1의 특이적 항체 분자 및/또는 이의 조합으로 구성된 군으로부터 선택되는 적어도 하나의 분자 및 약학적으로 허용가능한 담체를 포함하는 혈관신생억제 약학적 조성물에 관한 것이다. 또한 본 발명은 약제의 생산을 위한 상기 분자의 용도를 보호한다. | ||||||
QQ群二维码
意见反馈
意见反馈